

IN THE CLAIMS

Kindly cancel claims 1, 18 and 20.

Kindly amend the claims as follows\*:

5. (Amended) The method according to any one of claims 2 to 4, wherein ~~the~~ morphogenic protein is an osteogenic protein that ~~is~~ capable of inducing angiogenesis.

6. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein comprises an amino acid sequence selected from the group consisting of BMP-3, BMP-4, ~~BMP-5~~, BMP-6, OP-1 (BMP-7), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, COP-5, COP-7 and an amino acid sequence variant thereof, wherein the amino acid sequence variant has angiogenic activity.

7. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein is a monomeric species.

8. (Amended) The method according to claim 7, wherein the ~~monomeric~~ species is selected from the group consisting of OP-1, ~~BMP-5~~, BMP-6, BMP-8, GDF-6, GDF-7 and amino acid sequence variants thereof, wherein the amino acid sequence variant has angiogenic activity.

[  
\* An "Appendix of Claim Amendments" is enclosed at Tab B, showing the amendments to claims 5-7, 9, 11-13. In the Appendix, the added portion is underscored and the deleted portion is bracketed.]

9. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein comprises a disulfide bonded dimeric species.

---

10. (Amended) The method according to claim 9, wherein the dimeric species comprises a polypeptide selected from the group consisting of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and amino acid sequence variants thereof, wherein the amino acid sequence variant has angiogenic activity.

---

11. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein is OP-1.

12. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein is produced by the expression of a recombinant DNA molecule in a host cell.

---

13. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting of acidic fibroblast growth factor (aFGF), basic fibroblast growth factor FGF (bFGF), transforming growth factor- $\beta$  (TGF- $\beta$ ), transforming growth factor- $\alpha$  (TGF- $\alpha$ ), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), endothelial cell growth factor (ECGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), platelet activating factor (PAF), interleukin-8 (IL-8), placental growth factor (PGF), proliferin, B61, soluble vascular cell adhesion molecule-1 (SVCAM-1), soluble E-selectin, ephrin, 12-hydroxyeicosatetraenoic acid, tat protein of HIV-1, angiogenin, prostaglandin and amino

acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein.

14. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting of basic fibroblast growth factor (bFGF), platelet derived transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein.

15. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of basic fibroblast growth factor (bFGF) and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein.

16. (Amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of platelet derived transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein.